Serina Therapeutics (SER) Other Non-Current Liabilities (2022 - 2026)
Serina Therapeutics (SER) posted Other Non-Current Liabilities of $283000.0 for Q4 2025, down 84.96% sequentially from $1.9 million in Q3 2025, and down 92.1% YoY from $3.6 million in Q4 2024.
Serina Therapeutics (SER) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Serina Therapeutics has reported Other Non-Current Liabilities for 4 years, with the latest figure at $283000.0 in Q4 2025.
- Quarterly Other Non-Current Liabilities fell 92.1% year-over-year to $283000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $283000.0 (down 92.1% YoY) and the FY2025 annual result came in at $283000.0, down 92.1% from the prior year.
- Other Non-Current Liabilities fell to $283000.0 in Q4 2025 per SER's latest filing, from $1.9 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $24.1 million in Q1 2024 and troughed at $100000.0 in Q3 2023.
- A 4-year average of $4.3 million and a median of $1.7 million in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities surged 6839.19% in 2024, then slumped 92.1% in 2025.
- Over 4 years, Other Non-Current Liabilities stood at $180000.0 in 2022, then sank by 44.44% to $100000.0 in 2023, then soared by 3482.0% to $3.6 million in 2024, then plunged by 92.1% to $283000.0 in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $283000.0, $1.9 million, and $3.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Serina Therapeutics | 46.70 Mn | 23.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 113,000.00 |
| Dec 31, 2025 | 283,000.00 |
| Sep 30, 2025 | 1.88 Mn |
| Jun 30, 2025 | 3.55 Mn |
| Mar 31, 2025 | 2.59 Mn |
| Dec 31, 2024 | 3.58 Mn |
| Sep 30, 2024 | 6.74 Mn |
| Jun 30, 2024 | 13.41 Mn |
| Mar 31, 2024 | 24.08 Mn |
| Sep 30, 2023 | 100,000.00 |
| Mar 31, 2023 | 347,000.00 |
| Dec 31, 2022 | 180,000.00 |
| Sep 30, 2022 | 657,000.00 |
| Jun 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 1.62 Mn |